
Opinion|Videos|December 16, 2024
Spesolimab Efficacy Data
Key Takeaways
Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
4
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
5









